Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Exciting Update On ACH-3102


Dallas, Texas 04/09/2014 (FINANCIALSTRENDS) – Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) the drug maker which has been one of the lead biotechnology innovators to develop therapies for HCV has in a recent peer-reviewed presentation, reported updated results for its ACH-3102, clinical trial results. The company has been reviewing 150mg loading dosage, 50mg per day along with another drug called as sovaprevir, and the twice daily ribavirin while 100% of patients will achieve SVR12 n=8; will also look at Y93 mutations as the baseline.

Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) is at its bearish best, following the announcement of the results. With the results of the first quarter due by May 5, 2014, the upside for the company is high.

Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) is the biopharmaceutical company which has been developing solutions for treating infectious diseases. It has been developing antivirals which will treat conditions such as Chronic hepatitis C and will also develop anti-bacterials which will treat different forms of HCV: ACH-1625, which is a NS3 protease inhibitor for the treatment HCV.

Financial Updates

Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) currently holds a market price of $295.22 million. The stock trades on the stock market at prices ranging from $2.97 to $3.13. The company has also reported a 52 week high of $8.49 or $2.26 low.

Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) has also reported negative EPS of -0.61. The outstanding shares for this stock are 96.79 million.

Apparently, in the past week the biotechnology stocks have been marking progress at the browsers, based on sector based progress.

Biotechnology stocks which are currently offering such movement are – NeuralstemInc, Dyax Corp, too are showing movement with Dyax Corp. reporting FDA approval for its drug KALBITOR and CeuralstemInc, which has its study on NSI-566 stem cells in the brain published on medical journal PLOS ONE.

Achillion is expected to surge ahead on the basis of the positive results of its HCV drug therapies.